Company intelligence / Profile preview

Correlia Biosystems

Berkeley, California, United Statescorreliabio.com ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

Correlia Biosystems developed next-generation automated immunoassay platforms—most notably the PIXI system—enabling rapid, highly sensitive multiplexed protein quantification from ultra-low sample volumes. Their microfluidic technologies provide significant improvements over traditional ELISA in speed, automation, dynamic range, and sample conservation. The company's products have been adopted by leading pharmaceutical companies for biopharmaceutical analysis and proteomic research.

Modalities: DeviceMicrofluidics platformDiagnostic technology platform
Industry: Drug Discovery Services

Partnerships

Designed products in collaboration with five of the world’s top ten pharma companies.

Beyond the preview

Go deeper on Correlia Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Correlia Biosystems.

Explore the full profile